More than 10 million US patients will regain easy access to Eli Lilly & Co.’s obesity shot Zepbound through insurance after CVS Health Corp. reversed a controversial decision to restrict it for certain drug plans.
More than 10 million US patients will regain easy access to Eli Lilly & Co.’s obesity shot Zepbound through insurance after CVS Health Corp. reversed a controversial decision to restrict it for certain drug plans.
The reversal comes after Lilly agree... [309 chars]